News Quantified

RCUS – arcus biosciences, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

TIGIT Inhibitors Market Poised for Strong Growth Through 2034, Driven by Expanding Immuno-Oncology Pipeline | DelveInsight [Yahoo! Finance]

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences (NYSE:RCUS) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.

Arcus Biosciences (NYSE:RCUS) was upgraded by analysts at Wall Street Ze

Arcus Biosciences (NYSE:RCUS) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating.

-2.2%

BEAT

-1.4%

MISS

-1.0%

BEAT

-1.0%

BEAT

Form 4 Arcus Biosciences, Inc. For: Jan 23 Filed by: ROSEN TERRY J

Form 4 Arcus Biosciences, Inc. For: Jan 23 Filed by: Tang Carolyn C.

Form 4 Arcus Biosciences, Inc. For: Jan 23 Filed by: Markus Richard

Form 4 Arcus Biosciences, Inc. For: Jan 23 Filed by: Jaen Juan C.

Form 4 Arcus Biosciences, Inc. For: Jan 23 Filed by: Goeltz II Robert C.

Top News Gainers

9/26 Arcus Biosciences Inc (NYSE: RCUS) is now covered by analysts at Mizuho. They set a "buy" rating on the stock. 15.6%

2/18 Arcus Biosciences Inc (NYSE: RCUS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $13.00 price target on the stock. 12.7%

8/8 Arcus Biosciences Inc (NYSE: RCUS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 11.0%

3/4 Arcus Biosciences Inc (NYSE: RCUS) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $24.00 price target on the stock. 7.7%

6/11 Arcus Biosciences to Provide a Mid-Year Update on Clinical and Preclinical Programs 6.4%

11/12 Arcus Biosciences Inc (NYSE: RCUS) is now covered by analysts at SunTrust Banks, Inc.. They set a "buy" rating on the stock. 5.4%

4/9 Arcus Biosciences Announces New Employment Inducement Grants 5.3%

12/18 Arcus Biosciences, in Collaboration with Genentech, Announces Two Randomized Clinical Studies to Advance AB928, a Dual Adenosine Receptor Antagonist, into Novel Combinations for Colorectal and Pancreatic Cancers 4.9%

10/30 Form 4 Arcus Biosciences, Inc. For: Oct 28 Filed by: Ribas Antoni 4.5%

7/4 Arcus Biosciences Inc (NYSE: RCUS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $9.25 price target on the stock. 4.4%

Top News Decliners

3/14 Arcus Biosciences Inc (NYSE: RCUS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $17.00 price target on the stock. -24.3%

2/25 Arcus Biosciences Inc (NYSE: RCUS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -9.5%

11/25 Form 8-K/A Arcus Biosciences, Inc. For: Sep 10 -8.8%

4/7 Form 8-K Arcus Biosciences, Inc. For: Apr 07 -7.6%

11/7 Arcus Biosciences Inc (NYSE: RCUS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.3%

10/4 Form 3 Arcus Biosciences, Inc. For: Oct 01 Filed by: Barker Jason -6.7%

4/16 Arcus stock jumps on Bloomberg News report that Gilead may take a stake [MarketWatch] -6.3%

3/3 Arcus Biosciences Inc (NYSE: RCUS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $17.00 price target on the stock. -5.3%

2/22 3 Biotech Stocks That Soared This Week: Are They Buys? [The Motley Fool] -5.1%

2/26 Arcus Biosciences Inc (NYSE: RCUS) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $22.00 price target on the stock. -4.8%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day